ReviewEuropean journal of nuclear medicine and molecular imaging2017
Therapy assessment of bone metastatic disease in the era of
Review in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2021Trial
- Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair.Pharmaceutics · 2023Review
- Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.Future science OA · 2021Article
- uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.Diagnostics (Basel, Switzerland) · 2021Article
- Interim and end-treatmentScientific reports · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Article
- The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticals.European journal of nuclear medicine and molecular imaging · 2018Article
- Review
- Article
- Uptake of Radium-223 Dichloride and Early [Molecular imaging and biology · 2018Article
- Therapy monitoring with PET in cancer patients: achievements, opportunities and challenges ahead for the PET community.European journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDefining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management.
methods
resultsPET/CT imaging using various radiotracers such as
conclusionThis review examines the most recent publications related to this topic.
Indexed as
Identifiers
28567494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.